FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1967469454> ?p ?o ?g. }

• W1967469454 endingPage "526" @default.
• W1967469454 startingPage "522" @default.
• W1967469454 abstract "Background Chronic use of standard therapies for atopic dermatitis (AD) is associated with variable efficacy and potential side effects. Targeted therapeutic approaches, such as the inhibition of tumor necrosis factor–α, may be a novel option. Objective This investigator-initiated, open, prospective, single-center, pilot study was conducted to evaluate the long-term efficacy and safety of infliximab in patients with AD. Methods Nine patients with moderate or severe AD were enrolled. AD in these patients was resistant to conventional therapy. Infliximab 5 mg/kg was administered by intravenous infusion at weeks 0, 2, 6, 14, 22, 30, and 38, and patients were followed for 46 weeks. Results Induction therapy with infliximab significantly improved all clinical parameters, but this improvement was not sustained through maintenance therapy. Only two patients with severe AD achieved an excellent clinical response by 46 weeks. Conclusions Infliximab monotherapy may be an additional therapeutic option for the management of refractory severe AD. Chronic use of standard therapies for atopic dermatitis (AD) is associated with variable efficacy and potential side effects. Targeted therapeutic approaches, such as the inhibition of tumor necrosis factor–α, may be a novel option. This investigator-initiated, open, prospective, single-center, pilot study was conducted to evaluate the long-term efficacy and safety of infliximab in patients with AD. Nine patients with moderate or severe AD were enrolled. AD in these patients was resistant to conventional therapy. Infliximab 5 mg/kg was administered by intravenous infusion at weeks 0, 2, 6, 14, 22, 30, and 38, and patients were followed for 46 weeks. Induction therapy with infliximab significantly improved all clinical parameters, but this improvement was not sustained through maintenance therapy. Only two patients with severe AD achieved an excellent clinical response by 46 weeks. Infliximab monotherapy may be an additional therapeutic option for the management of refractory severe AD." @default.
• W1967469454 created "2016-06-24" @default.
• W1967469454 creator A5016157822 @default.
• W1967469454 creator A5034272199 @default.
• W1967469454 creator A5059789259 @default.
• W1967469454 creator A5064778812 @default.
• W1967469454 creator A5067435878 @default.
• W1967469454 date "2005-03-01" @default.
• W1967469454 modified "2023-09-26" @default.
• W1967469454 title "Infliximab in the treatment of moderate to severe atopic dermatitis" @default.
• W1967469454 cites W1977664790 @default.
• W1967469454 cites W1979594417 @default.
• W1967469454 cites W1985763670 @default.
• W1967469454 cites W1993306884 @default.
• W1967469454 cites W1994630556 @default.
• W1967469454 cites W2010753554 @default.
• W1967469454 cites W2020374736 @default.
• W1967469454 cites W2026116536 @default.
• W1967469454 cites W2053952900 @default.
• W1967469454 cites W2079001947 @default.
• W1967469454 cites W2098031731 @default.
• W1967469454 cites W2098276643 @default.
• W1967469454 cites W2110285242 @default.
• W1967469454 cites W2146304976 @default.
• W1967469454 cites W2150206066 @default.
• W1967469454 cites W4232510995 @default.
• W1967469454 doi "https://doi.org/10.1016/j.jaad.2004.11.022" @default.
• W1967469454 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15761436" @default.
• W1967469454 hasPublicationYear "2005" @default.
• W1967469454 type Work @default.
• W1967469454 sameAs 1967469454 @default.
• W1967469454 citedByCount "177" @default.
• W1967469454 countsByYear W19674694542012 @default.
• W1967469454 countsByYear W19674694542013 @default.
• W1967469454 countsByYear W19674694542014 @default.
• W1967469454 countsByYear W19674694542015 @default.
• W1967469454 countsByYear W19674694542016 @default.
• W1967469454 countsByYear W19674694542017 @default.
• W1967469454 countsByYear W19674694542018 @default.
• W1967469454 countsByYear W19674694542019 @default.
• W1967469454 countsByYear W19674694542020 @default.
• W1967469454 countsByYear W19674694542021 @default.
• W1967469454 countsByYear W19674694542022 @default.
• W1967469454 countsByYear W19674694542023 @default.
• W1967469454 crossrefType "journal-article" @default.
• W1967469454 hasAuthorship W1967469454A5016157822 @default.
• W1967469454 hasAuthorship W1967469454A5034272199 @default.
• W1967469454 hasAuthorship W1967469454A5059789259 @default.
• W1967469454 hasAuthorship W1967469454A5064778812 @default.
• W1967469454 hasAuthorship W1967469454A5067435878 @default.
• W1967469454 hasConcept C121332964 @default.
• W1967469454 hasConcept C126322002 @default.
• W1967469454 hasConcept C141071460 @default.
• W1967469454 hasConcept C142424586 @default.
• W1967469454 hasConcept C16005928 @default.
• W1967469454 hasConcept C17991360 @default.
• W1967469454 hasConcept C188816634 @default.
• W1967469454 hasConcept C2777138892 @default.
• W1967469454 hasConcept C2778329239 @default.
• W1967469454 hasConcept C2780073493 @default.
• W1967469454 hasConcept C535046627 @default.
• W1967469454 hasConcept C71924100 @default.
• W1967469454 hasConcept C87355193 @default.
• W1967469454 hasConceptScore W1967469454C121332964 @default.
• W1967469454 hasConceptScore W1967469454C126322002 @default.
• W1967469454 hasConceptScore W1967469454C141071460 @default.
• W1967469454 hasConceptScore W1967469454C142424586 @default.
• W1967469454 hasConceptScore W1967469454C16005928 @default.
• W1967469454 hasConceptScore W1967469454C17991360 @default.
• W1967469454 hasConceptScore W1967469454C188816634 @default.
• W1967469454 hasConceptScore W1967469454C2777138892 @default.
• W1967469454 hasConceptScore W1967469454C2778329239 @default.
• W1967469454 hasConceptScore W1967469454C2780073493 @default.
• W1967469454 hasConceptScore W1967469454C535046627 @default.
• W1967469454 hasConceptScore W1967469454C71924100 @default.
• W1967469454 hasConceptScore W1967469454C87355193 @default.
• W1967469454 hasIssue "3" @default.
• W1967469454 hasLocation W19674694541 @default.
• W1967469454 hasLocation W19674694542 @default.
• W1967469454 hasOpenAccess W1967469454 @default.
• W1967469454 hasPrimaryLocation W19674694541 @default.
• W1967469454 hasRelatedWork W1793302197 @default.
• W1967469454 hasRelatedWork W1860721670 @default.
• W1967469454 hasRelatedWork W1983134530 @default.
• W1967469454 hasRelatedWork W2120503240 @default.
• W1967469454 hasRelatedWork W2398622273 @default.
• W1967469454 hasRelatedWork W2528057197 @default.
• W1967469454 hasRelatedWork W2733319552 @default.
• W1967469454 hasRelatedWork W3013183041 @default.
• W1967469454 hasRelatedWork W3155819540 @default.
• W1967469454 hasRelatedWork W4293747143 @default.
• W1967469454 hasVolume "52" @default.
• W1967469454 isParatext "false" @default.
• W1967469454 isRetracted "false" @default.
• W1967469454 magId "1967469454" @default.
• W1967469454 workType "article" @default.